NEWCASTLE, England–(BUSINESS WIRE)–Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of preliminary data from its Phase 1 study for its HER2-directed ADC, IKS014, which is being assessed in patients with advanced or metastatic HER2+, HER2-low and HER2-mutated solid tumours, at the San Antonio Breast Cancer Symposium (SABCS), December 8-11, 2026, San Antonio, Texas. Additionally, the presentation includes a pooled an
